Evaluation of the safety and efficacy of micafungin in Japanese patients with deep mycosis: a post-marketing survey report
Abstract
The safety and efficacy of micafungin were evaluated in a Japanese post-marketing survey involving 1,142 patients with deep mycosis caused by Candida or Aspergillus. The overall clinical response was 83.0%, and the respective responses for patients with candidiasis or aspergillosis were 86.3 and 70.8%. With regard to drug reactions, 562 adverse reactions were observed in 28.5% of patients. Among the 83 serious adverse drug reactions reported by 53 patients, a causal relationship with micafungin was assessed as definite or probable for 6 reactions in 5 patients. Age and baseline hepatic and renal function status did not affect the incidence of adverse reactions, although incidence increased significantly in proportion to the severity of mycosis and daily dose (p < 0.01). In multiple logistic regression analysis, neither baseline hepatic impairment nor increased daily dose of micafungin affected the incidence of hepatobiliary disorders, however, the severity of mycosis was found to correlate significantly with hepatobiliary disorders (p = 0.031). Taken together, our post-marketing findings show that micafungin is effective against deep mycosis caused by Candida or Aspergillus in patients across a range of backgrounds.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Micafungin has been used as primary therapy in noncomparative studies of IA, with response rates ranging from 45% to 71%.
“The echinocandins caspofungin and micafungin have been used as primary therapy in noncomparative studies of IA, with response rates ranging from 33% to 57% for caspofungin (687–690) and 45% to 71% for micafungin (54, 479, 691).”
From Aspergillus fumigatus and Aspergillosis in 2019 (2019) · cites this paper as [691]
Cites
Pappas, P. G., Kauffman, C. A., Andes, D., Benjamin, D. K., Calandra, T. F., Edwards, J. E., Filler, S. G., Fisher, J. F., Kullberg, B.-J., Zeichner, L. O., et al. (2009) · Clinical Infectious Diseases · doi:10.1086/596757 · Cited by 3,191 · see citing works
Walsh, T. J., Anaissie, E. J., Denning, D. W., Herbrecht, R., Kontoyiannis, D. P., Marr, K. A., Morrison, V. A., Segal, B. H., Steinbach, W. J., Stevens, D. A., et al. (2008) · Clinical Infectious Diseases · doi:10.1086/525258 · Cited by 2,685 · see citing works
van Burik, J. H., Ratanatharathorn, V., Stepan, D. E., Miller, C. B., Lipton, J. H., Vesole, D. H., Bunin, N., Wall, D. A., Hiemenz, J., Satoi, Y., et al. (2004) · Clinical Infectious Diseases · doi:10.1086/422312 · Cited by 741 · see citing works
Kuse, E.-R., Chetchotisakd, P., da Cunha, C. A., Ruhnke, M., Barrios, C., Raghunadharao, D., Sekhon, J. S., Freire, A., Ramasubramanian, V., Demeyer, I., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60605-9 · Cited by 692 · see citing works
Segal, B. H. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0808853 · Cited by 659 · see citing works
Parczewska, O. K., Posaconazol, przeciwgrzybicze, L., Anidulafungina, Micafungina, & wrażliwość, O. (2009) · Cited by 656 · see citing works
Micafungin versus Caspofungin for Treatment of Candidemia and Other Forms of Invasive Candidiasis
Pappas, P. G., Rotstein, C. M. F., Betts, R. F., Nucci, M., Talwar, D., De Waele, J. J., Vazquez, J. A., Dupont, B. F., Horn, D. L., Ostrosky-Zeichner, L., et al. (2007) · Clinical Infectious Diseases · doi:10.1086/520980 · Cited by 638 · see citing works
Maertens, J. A., Marchetti, O., Herbrecht, R., Cornely, O. A., Flückiger, U. M., Frère, P., Gachot, B., Heinz, W., Lass‐Flörl, C., Ribaud, P., et al. (2010) · Bone Marrow Transplantation · doi:10.1038/bmt.2010.175 · Cited by 465 · see citing works
Denning, D. W., Marr, K. A., Lau, W. M., Facklam, D., Ratanatharathorn, V., Becker, C., Ullmann, A. J., Seibel, N. L., Flynn, P. M., van Burik, J. H., et al. (2006) · Journal of Infection · doi:10.1016/j.jinf.2006.03.003 · Cited by 293 · see citing works
Micafungin: A New Echinocandin
Chandrasekar, P. H., & Sobel, J. D. (2006) · Clinical Infectious Diseases · doi:10.1086/501020 · Cited by 255 · see citing works
Recent trends in the epidemiology of invasive mycoses
Clark, T. A., & Hajjeh, R. A. (2002) · Current Opinion in Infectious Diseases · doi:10.1097/00001432-200212000-00003 · Cited by 210 · see citing works
Wet, N. T. E. D., Llanos‐Cuentas, A., Suleiman, J. M. A. H., Baraldi, E., Krantz, E., Negra, M. D., & Diekmann-Berndt, H. (2004) · Clinical Infectious Diseases · doi:10.1086/423377 · Cited by 203 · see citing works
Ostrosky-Zeichner, L., Kontoyiannis, D., Raffalli, J., Mullane, K. M., Vazquez, J., Anaissie, E. J., Lipton, J., Jacobs, P., Rensburg, J. H. J., Rex, J. H., et al. (2005) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-005-0024-8 · Cited by 189 · see citing works
Kohno, S., Masaoka, T., Yamaguchi, H., Mori, T., Urabe, A., Ito, A., Niki, Y., & IKEMOTO, H. (2004) · Scandinavian Journal of Infectious Diseases · doi:10.1080/00365540410020406 · Cited by 152 · see citing works
Wet, N. T. E. D., Bester, A. J., Viljoen, J., Filho, F. A. B. D. O., Suleiman, J. M. A. H., Ticona, E., Llanos, E. A., Fisco, C., Lau, W. M., & Buell, D. N. (2005) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2005.02427.x · Cited by 144 · see citing works
Pappas, P. G., Rotstein, C. M. F., Rf, B., Nucci, M., Talwar, D., Waele, J. J. D., Jm, D. L. V. V., Dupont, B., Horn, D., Ostrosky‐Zeichner, L., et al. (2008) · Ghent University Academic Bibliography (Ghent University) · Cited by 130 · see citing works
Treatment of Invasive Candidal Infections: Systematic Review and Meta-analysis
Gafter‐Gvili, A., Vidal, L., Goldberg, E., Leibovici, L., & Paul, M. (2008) · Mayo Clinic Proceedings · doi:10.4065/83.9.1011 · Cited by 97 · see citing works
Sirohi, B., Powles, R. L., Chopra, R., Russell, N. H., Byrne, J., Prentice, H. G., Potter, M. N., & Koblinger, S. (2006) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1705398 · Cited by 93 · see citing works
Successful treatment of oesophageal candidiasis by micafungin: a novel systemic antifungal agent
Pettengell, K., Mynhardt, J., Kluyts, T., Lau, W. M., Facklam, D., Buell, D. N., & the FK463 South African Study Group (2004) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2004.02083.x · Cited by 75 · see citing works
Jarvis, B., Figgitt, D. P., & Scott, L. J. (2004) · Drugs · doi:10.2165/00003495-200464090-00004 · Cited by 70 · see citing works
Kubiak, D. W., Porter, J., McDonnell, A., Delgado-Flores, J. O., Mui, E., Baden, L. R., & Marty, F. M. (2010) · Clinical Therapeutics · doi:10.1016/j.clinthera.2010.04.005 · Cited by 62 · see citing works
Tamura, K., Urabe, A., Yoshida, M., Kanamaru, A., Kodera, Y., Okamoto, S., Maesaki, S., & Masaoka, T. (2009) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190802635500 · Cited by 43 · see citing works
Role of Micafungin in the Antifungal Armamentarium
Ikeda, F., Tanaka, S., Ohki, H., et al. (2007) · Current Medicinal Chemistry · doi:10.2174/092986707780597970 · Cited by 34 · see citing works
Clinical efficacy of micafungin for chronic pulmonary aspergillosis
Izumikawa, K., Ohtsu, Y., Kawabata, M., Takaya, H., Miyamoto, A., Sakamoto, S., Kishi, K., Tsuboi, E., Homma, S. A., & Yoshimura, K. (2007) · Medical Mycology · doi:10.1080/13693780701278386 · Cited by 33 · see citing works
Kume, H., Yamazaki, T., Abe, M., et al. (2006) · Nippon Ishinkin Gakkai Zasshi · doi:10.3314/jjmm.47.15 · Cited by 32 · see citing works
Aikawa, N., Kusachi, S., Oda, S., Takesue, Y., & Tanaka, H. (2009) · Journal of Infection and Chemotherapy · doi:10.1007/s10156-009-0689-5 · Cited by 17 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Aspergillus fumigatus and Aspergillosis in 2019
Latgé, J.-P., & Chamilos, G. (2019) · Clinical Microbiology Reviews · doi:10.1128/cmr.00140-18 · Cited by 1,400 · see citing works
- Authors
- Hanadate, T., Wakasugi, M., Sogabe, K., Kobayashi, T., Horita, H., Kawamura, I., Matsui, K., Sou, M., Hori, Y., & Hoshino, Y.
- Affiliations
- Astellas Pharma (Japan) (JP)
- Corresponding author
- Hanadate, Tomoko
- Venue
- Journal of Infection and Chemotherapy
- Publisher
- Elsevier BV
- Published
- 2011
- Volume
- 17
- Issue
- 5
- Pages
- 622-632
- ISSN
- 1341-321X (ISSN-L)
- OpenAlex
- W2063203063
- Cited by
- 21
- References
- 26
- Citations by year
- 2025: 1 · 2024: 2 · 2021: 2 · 2019: 1 · 2018: 2 · 2017: 1 · 2015: 4 · 2014: 3 · 2013: 1 · 2012: 3
- FWCI
- 1.73
- Type
- journal article
- Language
- en
- Update notices
- erratum (2011-01-01)
- Open access
- closed
- Locations
- Journal of Infection and Chemotherapy (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Astellas Foundation for Research on Metabolic Disorders
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Health Sciences › Medicine › Epidemiology › Fungal Infections and Studies
- Keywords
- micafungin, deep mycosis, candidiasis, aspergillosis, antifungal efficacy, drug safety, adverse drug reactions, hepatobiliary diseases, Candida, Aspergillus, post-marketing surveillance, Japanese patients
- MeSH terms
- Micafungin, Adolescent, Adult, Aged, Aged, 80 and over, Aspergillosis, Aspergillus, Candida, Candidiasis, Female, Humans, Japan, Male, Middle Aged, Product Surveillance, Postmarketing, Prospective Studies, Risk Factors, Treatment Outcome, Echinocandins, Lipopeptides
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
